NL7909199A - Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. - Google Patents

Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. Download PDF

Info

Publication number: NL7909199A
Authority: NL; Netherlands
Prior art keywords: thiazolidine; carboxylic acid; pharmaceutically acceptable; acceptable salt; agent
Prior art date: 1978-12-21

Application number

NL7909199A

Other languages

English (en)

Dutch (nl)

Original Assignee

Gosalvez Mario

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-12-21

Filing date

1979-12-20

Publication date

1980-06-24

1979-12-20 Application filed by Gosalvez Mario filed Critical Gosalvez Mario

1980-06-24 Publication of NL7909199A publication Critical patent/NL7909199A/nl

Links

238000000034 method Methods 0.000 title claims description 19
201000010099 disease Diseases 0.000 title claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 claims description 50
206010028980 Neoplasm Diseases 0.000 claims description 34
150000003839 salts Chemical class 0.000 claims description 29
230000030944 contact inhibition Effects 0.000 claims description 16
239000000243 solution Substances 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
229940127089 cytotoxic agent Drugs 0.000 claims description 9
239000008176 lyophilized powder Substances 0.000 claims description 9
230000008569 process Effects 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
239000002254 cytotoxic agent Substances 0.000 claims description 7
159000000000 sodium salts Chemical class 0.000 claims description 7
230000037396 body weight Effects 0.000 claims description 6
230000012010 growth Effects 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
-1 alkali metal salt Chemical class 0.000 claims description 5
231100000599 cytotoxic agent Toxicity 0.000 claims description 5
229930195725 Mannitol Natural products 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
230000003211 malignant effect Effects 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 3
239000002585 base Substances 0.000 claims description 3
238000010255 intramuscular injection Methods 0.000 claims description 3
239000007927 intramuscular injection Substances 0.000 claims description 3
238000010253 intravenous injection Methods 0.000 claims description 3
238000006386 neutralization reaction Methods 0.000 claims description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
150000001342 alkaline earth metals Chemical class 0.000 claims description 2
150000001768 cations Chemical class 0.000 claims description 2
229960002949 fluorouracil Drugs 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
239000007924 injection Substances 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims 2
239000003513 alkali Substances 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229910052751 metal Inorganic materials 0.000 claims 1
239000002184 metal Substances 0.000 claims 1
230000000979 retarding effect Effects 0.000 claims 1
210000004027 cell Anatomy 0.000 description 35
201000011510 cancer Diseases 0.000 description 23
238000011282 treatment Methods 0.000 description 21
238000002474 experimental method Methods 0.000 description 12
150000001875 compounds Chemical class 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000000126 substance Substances 0.000 description 7
230000001472 cytotoxic effect Effects 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000009466 transformation Effects 0.000 description 5
201000008827 tuberculosis Diseases 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
241000282412 Homo Species 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
231100000065 noncytotoxic Toxicity 0.000 description 4
230000002020 noncytotoxic effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
206010027458 Metastases to lung Diseases 0.000 description 3
KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
208000037841 lung tumor Diseases 0.000 description 3
239000000203 mixture Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061934 Salivary gland cancer Diseases 0.000 description 2
208000033781 Thyroid carcinoma Diseases 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
201000003911 head and neck carcinoma Diseases 0.000 description 2
210000003632 microfilament Anatomy 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
201000003804 salivary gland carcinoma Diseases 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
208000013077 thyroid gland carcinoma Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100013460 Mus musculus Ftl2 gene Proteins 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010063493 Premature ageing Diseases 0.000 description 1
208000032038 Premature aging Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000008312 Tooth Loss Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960004279 formaldehyde Drugs 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical compound O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicinal Preparation (AREA)

NL7909199A 1978-12-21 1979-12-20 Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. NL7909199A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US05/971,729 US4384001A (en)	1978-12-21	1978-12-21	Treatment of tumors with thiazolidine-4-carboxylic acid
US97172978		1978-12-21

Publications (1)

Publication Number	Publication Date
NL7909199A true NL7909199A (nl)	1980-06-24

Family

ID=25518727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL7909199A NL7909199A (nl)	1978-12-21	1979-12-20	Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan.

Country Status (16)

Country	Link
US (1)	US4384001A (da)
JP (1)	JPS55115822A (da)
AU (1)	AU5390579A (da)
BE (1)	BE880744A (da)
CA (1)	CA1149284A (da)
DE (1)	DE2951050A1 (da)
DK (1)	DK542979A (da)
ES (1)	ES8102108A1 (da)
FR (1)	FR2444459A1 (da)
GB (1)	GB2039736B (da)
IL (1)	IL58948A0 (da)
IT (1)	IT1193348B (da)
LU (1)	LU82013A1 (da)
NL (1)	NL7909199A (da)
SE (1)	SE7910300L (da)
ZA (1)	ZA796918B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE53332B1 (en) *	1980-03-14	1988-10-26	Efamol Ltd	Pharmaceutical compositions
JPS57128625A (en) *	1981-01-30	1982-08-10	Rikagaku Kenkyusho	Carcinostatic
US4335210A (en) *	1981-02-11	1982-06-15	Cornell Research Foundation	Method of producing L-cysteine
FR2547729B1 (fr) *	1983-06-24	1986-05-02	Riker Laboratories Inc	Medicament a base d'acide dl thiazolidine carboxylique
FR2547728B1 (fr) *	1983-06-24	1986-05-02	Riker Laboratories Inc	Medicament a base d'acide d thiazolidine carboxylique
DE3586683T2 (de) *	1984-12-18	1993-04-08	Clark Pharma Dev	Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln.
JPH066578B2 (ja) *	1985-12-27	1994-01-26	三共株式会社	チアゾリジン誘導体
JPH01170063U (da) *	1988-05-11	1989-11-30
JPH0467539U (da) *	1990-10-18	1992-06-16
DE69214467T3 (de) *	1991-01-10	2000-09-28	Transcend Therapeutics, Inc.	Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom
PL181867B1 (pl) *	1994-06-14	2001-09-28	Dainippon Pharmaceutical Co	Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL
ES2277787B1 (es) *	2006-01-02	2008-06-16	Universidad De Cadiz	Empleo de tioprolina en tratamientos de reduccion de peso corporal.

1978
- 1978-12-21 US US05/971,729 patent/US4384001A/en not_active Expired - Lifetime
1979
- 1979-12-12 GB GB7942753A patent/GB2039736B/en not_active Expired
- 1979-12-13 IL IL58948A patent/IL58948A0/xx unknown
- 1979-12-14 SE SE7910300A patent/SE7910300L/xx unknown
- 1979-12-17 AU AU53905/79A patent/AU5390579A/en not_active Abandoned
- 1979-12-18 IT IT28170/79A patent/IT1193348B/it active
- 1979-12-19 CA CA000342263A patent/CA1149284A/en not_active Expired
- 1979-12-19 LU LU82013A patent/LU82013A1/fr unknown
- 1979-12-19 DE DE19792951050 patent/DE2951050A1/de not_active Withdrawn
- 1979-12-19 FR FR7931158A patent/FR2444459A1/fr active Granted
- 1979-12-19 ES ES487052A patent/ES8102108A1/es not_active Expired
- 1979-12-19 DK DK542979A patent/DK542979A/da unknown
- 1979-12-19 BE BE0/198657A patent/BE880744A/fr not_active IP Right Cessation
- 1979-12-20 ZA ZA00796918A patent/ZA796918B/xx unknown
- 1979-12-20 JP JP16495079A patent/JPS55115822A/ja active Granted
- 1979-12-20 NL NL7909199A patent/NL7909199A/nl not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA796918B (en)	1980-11-26
CA1149284A (en)	1983-07-05
GB2039736A (en)	1980-08-20
AU5390579A (en)	1980-06-26
DK542979A (da)	1980-06-22
IT7928170A0 (it)	1979-12-18
GB2039736B (en)	1983-04-13
SE7910300L (sv)	1980-06-22
JPS6328045B2 (da)	1988-06-07
FR2444459B1 (da)	1983-04-01
ES487052A0 (es)	1980-12-16
ES8102108A1 (es)	1980-12-16
IL58948A0 (en)	1980-03-31
DE2951050A1 (de)	1980-07-10
JPS55115822A (en)	1980-09-06
LU82013A1 (fr)	1981-02-03
FR2444459A1 (fr)	1980-07-18
US4384001A (en)	1983-05-17
IT1193348B (it)	1988-06-15
BE880744A (fr)	1980-06-19

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1985-08-01	BV	The patent application has lapsed

Publication	Publication Date	Title
RU2162327C2 (ru)	2001-01-27	Лечение рака и профилактика метастазирования
US11090330B2 (en)	2021-08-17	Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same
US6579891B1 (en)	2003-06-17	Agent and method for prevention and treatment of cancer in animals
US6407125B1 (en)	2002-06-18	Pharmacological agent and method of treatment
JPH0662407B2 (ja)	1994-08-17	安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
US4384001A (en)	1983-05-17	Treatment of tumors with thiazolidine-4-carboxylic acid
US6403618B1 (en)	2002-06-11	Agent and method for controlling angiogenesis
AU709620B2 (en)	1999-09-02	New applications of lysozyme dimer
KR20060061367A (ko)	2006-06-07	디파이브로타이드를 단독으로 또는 다른 항암제들과조합하여 포함하는 항암제제
US6183742B1 (en)	2001-02-06	Applications of lysozyme dimer
Taliaferro	1948	The Role of the Spleen and the Lymphoid-macrophage System in the Quinine Treatment of Gallinaceum Malaria: I. Acquired Immunity and Phagocytosis
JPS6379824A (ja)	1988-04-09	制癌剤
US6441009B1 (en)	2002-08-27	Agent and method of preventing and treating heavy metal exposure and toxicity
CN113456643B (zh)	2022-04-01	一种含普那布林的药物组合及其应用
Sadrolhefazi et al.	2007	Allopurinol mouthwash for prevention or alleviation radiotherapy induced oral mucositis: a randomized, placebo-controlled trial
KR20060038387A (ko)	2006-05-03	화학요법을 받고 있는 암 환자를 치료하는 방법
CN111249274B (zh)	2022-04-01	银杏内酯b在制备胶质瘤细胞活性抑制剂中的应用
Boughattas et al.	1996	Modulation of cisplatin chronotoxicity related to reduced glutathione in mice
RU2282437C1 (ru)	2006-08-27	Средство для лечения болезней суставов
CN111514290A (zh)	2020-08-11	一种葫芦素组合物及其用途
NL8501840A (nl)	1986-01-16	Inhibitie van tumorontwikkeling.
RU2680804C1 (ru)	2019-02-27	Стабильное средство лечения болезней суставов
RU2119334C1 (ru)	1998-09-27	Антгельминтное средство
US20130079416A1 (en)	2013-03-28	Homeopathic medicament comprising phenacetin for the treatment of cancer
RU2681546C1 (ru)	2019-03-11	Способ экстренной профилактики клещевого вирусного энцефалита